Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQG202
- Development stage
- Phase 3
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
**TQG202** is a recombinant human coagulation **factor VIII** (FVIII) product with a **B-domain deleted** structure, designed for the treatment of **hemophilia A**. It functions by replacing the deficient or defective FVIII in patients, thereby restoring normal blood clotting to prevent or control bleeding episodes. Developed by **Chia Tai Tianqing Pharmaceutical** under license from **Alphamab**, it has demonstrated **bioequivalence** to **Xyntha** (another B-domain-deleted recombinant FVIII), effective bleeding control in on-demand treatment for moderate/severe cases, and promising efficacy with good tolerability in prophylaxis for severe hemophilia A.[3][5][1]
- Brand names
- NuwiqXynthaRecombinateTQG202TQG-202TQG 202Esperoct
- Other names
- b-domain deleted rFVIIIBDD-rFVIIIBDD recombinant factor VIII
02
Targets
F8 (Coagulation Factor VIIIa)
Beyond the preview
Go deeper on TQG202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQG202.